KemPharm, Inc. Announces Initiation of Phase 1 Trial of KP201 for Pain
Published: Feb 22, 2011
NORTH LIBERTY, Iowa--(BUSINESS WIRE)--KemPharm, Inc. today announced that it has commenced a Phase 1 clinical trial in healthy volunteers with KP201, its novel abuse deterrent prodrug of hydrocodone for pain. KP201 is a new chemical entity (NCE) and is the most advanced opioid-based lead candidate in KemPharm’s emerging pipeline. KemPharm’s technology provides a way to impart improved properties to new drug candidates through chemical modification of existing FDA-approved drugs. KP201 now joins KemPharm’s clinical pipeline, which includes the more advanced Phase 2 candidate KP106, a prodrug for the treatment of attention-deficit hyperactivity disorder (ADHD).